康臣藥業(1681.HK)拉昇創逾2年新高 年內累漲超70%
格隆匯5月17日丨康臣藥業(1681.HK)大肆拉昇,目前漲8.11%報5.33港元,股價創2019年3月以來新高,市值44億港元;該股年內已累漲超70%。招商證券香港日前發研報稱,康臣藥業管理層預計玉林製藥將於2021年底完成持續一年多的渠道庫存清理,為增長復甦奠定基礎;目前康臣藥業估值處於歷史低位,且股息和回購增厚投資回報,維持“買入”評級,目標價由7.7港元上調14.3%至8.8港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.